Interleukin-31 and Pruritic Skin
暂无分享,去创建一个
[1] J. Paolini,et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin‐31, oncostatin M, IL‐31 receptor alpha and oncostatin M receptor beta , 2021, Experimental dermatology.
[2] C. Foocharoen,et al. Increased serum IL-31 levels in chronic spontaneous urticaria and psoriasis with pruritic symptoms , 2020, Heliyon.
[3] M. Obeidat,et al. Elevated interleukin 31 serum levels in hemodialysis patients are associated with uremic pruritus. , 2020, Cytokine.
[4] S. Kwatra,et al. Health-related quality of life and economic burden of chronic pruritus. , 2020, The Journal of investigative dermatology.
[5] M. Hoon,et al. The Cytokine TGF-β Induces Interleukin-31 Expression from Dermal Dendritic Cells to Activate Sensory Neurons and Stimulate Wound Itching , 2020, Immunity.
[6] M. Kawashima,et al. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. , 2020, The New England journal of medicine.
[7] T. Akiyama,et al. New insights into the mechanisms behind mechanical itch , 2020, Experimental dermatology.
[8] K. Sawanyawisuth,et al. Interleukin-31 and Chronic Pruritus of Unknown Origin , 2020, Biomarker insights.
[9] B. Wang,et al. Inhibition of mite‐induced dermatitis, pruritus, and nerve sprouting in mice by the endothelin receptor antagonist bosentan , 2020, Allergy.
[10] S. Feldman,et al. New and Emerging Systemic Treatments for Atopic Dermatitis , 2020, Drugs.
[11] Brian S. Kim,et al. New and Emerging Treatments for Inflammatory Itch. , 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[12] Liang Han,et al. Visualizing the itch-sensing skin arbors , 2020, bioRxiv.
[13] T. Bieber,et al. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. , 2020, The New England journal of medicine.
[14] T. Hashimoto,et al. Pathophysiological mechanisms of itch in bullous pemphigoid. , 2020, Journal of the American Academy of Dermatology.
[15] T. Hashimoto,et al. Mechanisms of itch in stasis dermatitis: Significant role of IL-31 from macrophages. , 2020, The Journal of investigative dermatology.
[16] M. Steinhoff,et al. Interleukin‐4 and interleukin‐13 evoke scratching behaviour in mice , 2019, Experimental dermatology.
[17] M. Furue,et al. Selective role of neurokinin B in IL-31-induced itch response in mice. , 2019, The Journal of allergy and clinical immunology.
[18] S. Garg,et al. Alterations in circulating concentrations of IL-17, IL-31 and total IgE in dogs with atopic dermatitis. , 2019, Veterinary dermatology.
[19] M. Furue,et al. IL-4 Augments IL-31/IL-31 Receptor Alpha Interaction Leading to Enhanced Ccl 17 and Ccl 22 Production in Dendritic Cells: Implications for Atopic Dermatitis , 2019, International journal of molecular sciences.
[20] M. Szczepanik,et al. The influence of treatment with lokivetmab on transepidermal water loss (TEWL) in dogs with spontaneously occurring atopic dermatitis. , 2019, Veterinary dermatology.
[21] M. Furue,et al. Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study , 2019, The Journal of dermatology.
[22] T. Hashimoto,et al. Pruritus in ordinary scabies: IL‐31 from macrophages induced by overexpression of thymic stromal lymphopoietin and periostin , 2019, Allergy.
[23] T. Olivry,et al. Proactive maintenance therapy of canine atopic dermatitis with the anti‐IL‐31 lokivetmab. Can a monoclonal antibody blocking a single cytokine prevent allergy flares? , 2019, Veterinary dermatology.
[24] J. Silverberg,et al. Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus. , 2019, The Journal of allergy and clinical immunology.
[25] M. Furue,et al. Nemolizumab in patients with moderate‐to‐severe atopic dermatitis: Randomized, phase II, long‐term extension study , 2018, The Journal of allergy and clinical immunology.
[26] M. Furue,et al. Emerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis , 2018, Allergy.
[27] Tsukasa Suzuki,et al. Cynomolgus monkey model of interleukin‐31‐induced scratching depicts blockade of human interleukin‐31 receptor A by a humanized monoclonal antibody , 2018, Experimental dermatology.
[28] H. Moyaert,et al. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client‐owned dogs with atopic dermatitis , 2017, Veterinary dermatology.
[29] Jonathan R. Brestoff,et al. Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch , 2017, Cell.
[30] S. Gangemi,et al. Interleukin 31 is involved in intrahepatic cholestasis of pregnancy , 2017, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[31] M. Furue,et al. Itch in Atopic Dermatitis. , 2017, Immunology and allergy clinics of North America.
[32] M. Furue,et al. The transcription factor EPAS1 links DOCK8 deficiency to atopic skin inflammation via IL-31 induction , 2017, Nature Communications.
[33] S. Dillon,et al. Interleukin (IL) 31 induces in cynomolgus monkeys a rapid and intense itch response that can be inhibited by an IL‐31 neutralizing antibody , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[34] T. Ruzicka,et al. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. , 2017, The New England journal of medicine.
[35] S. Dunham,et al. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. , 2016, Veterinary dermatology.
[36] A. Jegga,et al. IL-31-Driven Skin Remodeling Involves Epidermal Cell Proliferation and Thickening That Lead to Impaired Skin-Barrier Function , 2016, PloS one.
[37] J. Kere,et al. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. , 2016, The Journal of allergy and clinical immunology.
[38] A. Kim,et al. Control of the Physical and Antimicrobial Skin Barrier by an IL-31–IL-1 Signaling Network , 2016, The Journal of Immunology.
[39] J. Guitart,et al. Cutaneous T-cell Lymphoma and Pruritus: The Expression of IL-31 and its Receptors in the Skin. , 2016, Acta dermato-venereologica.
[40] H. Nakagawa,et al. The first trial of CIM331, a humanized antihuman interleukin‐31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double‐blind, placebo‐controlled study , 2016, The British journal of dermatology.
[41] R. Mccall,et al. IL‐31‐induced pruritus in dogs: a novel experimental model to evaluate anti‐pruritic effects of canine therapeutics , 2015, Veterinary dermatology.
[42] E. Carstens,et al. Central Mechanisms of Itch. , 2016, Current problems in dermatology.
[43] M. Furue,et al. New therapies for controlling atopic itch , 2015, The Journal of dermatology.
[44] A. Duschl,et al. Prerequisites for Functional Interleukin 31 Signaling and Its Feedback Regulation by Suppressor of Cytokine Signaling 3 (SOCS3)* , 2015, The Journal of Biological Chemistry.
[45] R. Kakigi,et al. Itch and brain , 2015, The Journal of dermatology.
[46] S. Akira,et al. STAT3-dependent reactive astrogliosis in the spinal dorsal horn underlies chronic itch , 2015, Nature Medicine.
[47] DengYong,et al. Elevated TGF-β1/IL-31 Pathway Is Associated with the Disease Severity of Hepatitis B Virus–Related Liver Cirrhosis , 2015 .
[48] G. Yosipovitch,et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. , 2015, Clinical immunology.
[49] A. Jegga,et al. Th2 Cytokines Augment IL-31/IL-31RA Interactions via STAT6-dependent IL-31RA Expression* , 2015, The Journal of Biological Chemistry.
[50] M. Sokołowska-Wojdyło,et al. Il-31 does not correlate to pruritus related to early stage cutaneous T-cell lymphomas but is involved in pathogenesis of the disease. , 2015, Acta dermato-venereologica.
[51] S. Jee,et al. Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis. , 2014, Journal of the American Academy of Dermatology.
[52] P. Nibbering,et al. Reduced filaggrin expression is accompanied by increased Staphylococcus aureus colonization of epidermal skin models , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[53] N. Yamashita,et al. Anti‐IL‐31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice , 2014, British journal of pharmacology.
[54] D. Ribatti,et al. The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma , 2014, Leukemia.
[55] D. Werner,et al. Human Th2 but Not Th9 Cells Release IL-31 in a STAT6/NF-κB–Dependent Way , 2014, The Journal of Immunology.
[56] A. Morita,et al. Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis. , 2014, Journal of dermatological science.
[57] T. Buhl,et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1. , 2014, The Journal of allergy and clinical immunology.
[58] M. Hoon,et al. Why we scratch an itch: the molecules, cells and circuits of itch , 2014, Nature Neuroscience.
[59] M. Maurer,et al. Interleukin‐31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge , 2014, Allergy.
[60] S. Hubchak,et al. Hypoxia-inducible factor-2α and TGF-β signaling interact to promote normoxic glomerular fibrogenesis. , 2013, American journal of physiology. Renal physiology.
[61] E. Carstens,et al. Neural processing of itch , 2013, Neuroscience.
[62] J. Bonaventura,et al. Hemoglobin-induced endothelial cell permeability is controlled, in part, via a myeloid differentiation primary response gene-88-dependent signaling mechanism. , 2013, American journal of respiratory cell and molecular biology.
[63] S. Durham,et al. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. , 2013, The Journal of allergy and clinical immunology.
[64] K. Sayama,et al. Eccrine Sweat Contains IL-1α, IL-1β and IL-31 and Activates Epidermal Keratinocytes as a Danger Signal , 2013, PloS one.
[65] J. Collins,et al. Transcription Factors Sp1 and Hif2α Mediate Induction of the Copper-transporting ATPase (Atp7a) Gene in Intestinal Epithelial Cells during Hypoxia* , 2013, The Journal of Biological Chemistry.
[66] T. Werfel,et al. Interleukin (IL)‐31 activates signal transducer and activator of transcription (STAT)‐1, STAT‐5 and extracellular signal‐regulated kinase 1/2 and down‐regulates IL‐12p40 production in activated human macrophages , 2013, Allergy.
[67] R. Mccall,et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. , 2013, Veterinary dermatology.
[68] S. Kežić,et al. Increased frequencies of IL‐31‐producing T cells are found in chronic atopic dermatitis skin , 2012, Experimental dermatology.
[69] R. Fölster-Holst,et al. IL‐31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis , 2012, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[70] Y. Tada,et al. Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma. , 2012, Acta dermato-venereologica.
[71] Y. Miyagi,et al. HIF2α-Sp1 interaction mediates a deacetylation-dependent FVII-gene activation under hypoxic conditions in ovarian cancer cells , 2012, Nucleic acids research.
[72] B. Lüscher,et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. , 2012, The Journal of allergy and clinical immunology.
[73] L. French,et al. IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. , 2012, Acta dermato-venereologica.
[74] A. Kim,et al. Ultraviolet B radiation and reactive oxygen species modulate interleukin‐31 expression in T lymphocytes, monocytes and dendritic cells , 2011, The British journal of dermatology.
[75] A. Heratizadeh,et al. Staphylococcal α-Toxin Induces a Higher T Cell Proliferation and Interleukin-31 in Atopic Dermatitis , 2011, International Archives of Allergy and Immunology.
[76] T. Werfel,et al. Functional effects of interleukin 31 in human primary keratinocytes , 2011, Allergy.
[77] Riitta Lahesmaa,et al. Genomic views of STAT function in CD4+ T helper cell differentiation , 2011, Nature Reviews Immunology.
[78] MHM Ezzat,et al. Serum measurement of interleukin‐31 (IL‐31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.
[79] M. Furue,et al. Collared mice: a model to assess the effects of scratching. , 2010, Journal of dermatological science.
[80] K. Matsushima,et al. Anti‐interleukin‐31‐antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis , 2009, Experimental dermatology.
[81] M. Steinhoff,et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. , 2006, The Journal of allergy and clinical immunology.
[82] B. Harder,et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. , 2006, The Journal of allergy and clinical immunology.
[83] Scott R. Presnell,et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice , 2004, Nature Immunology.
[84] R. McIntyre,et al. Toll-like receptor-4 signaling mediates pulmonary neutrophil sequestration in response to gram-positive bacterial enterotoxin. , 2002, The Journal of surgical research.